Editorial: establishing a joint approach to a common problem for gastroenterologists
Despite their name, the IBDs are systemic diseases in which gut manifestations are the predominant, and usually the initial, features.
As such, IBD patients may require cross-specialty referrals through the course of their disease. With increasing specialisation within medicine, it is not surprising that gastroenterologists may feel uncomfortable with the assessment and management of extraintestinal manifestations of IBD. 1 NSAIDs. 8, 9 This discrepancy has been attributed to their differing chemistry and pharmacodynamics. 10 Hence, whether COX-2 selective NSAIDs as a class are safe in IBD is unknown. Given these uncertainties, we agree that caution or indeed NSAID avoidance should be applied in patients with active bowel inflammation, with referral for a rheumatology opinion made based on inflammatory back pain alone.
For patients without active IBD, both physicians and patients should be vigilant for worsening disease activity.
In a multi-system disorder such as IBD, a multidisciplinary, cross-specialty approach is to the benefit of patients with extrain- shown that vedolizumab (VDZ) is of low risk during pregnancy, with comparable rates of preterm birth and mean birth rate compared to anti-tumour necrosis factor (anti-TNF) and no biologics. 1, 2 A higher rate of spontaneous abortion was reported in one study;
however, the women receiving VDZ had already failed on at least one biologic, and likely represent a population with more severe IBD. 2 A pregnancy clinical care pathway was published with recommendations to continue VDZ throughout pregnancy, planning for the last dose to be given 6-10 weeks before estimated date of confinement. 3 The paper by Moens et al compares the effects of VDZ with anti-TNF and with conventional/non-biologic medications. 4 This is a retrospective multicenter case-control study that included 79 pregnancies in 73 women exposed to VDZ (VDZE) with control groups of women exposed to anti-TNF (TNFE) and those who were immunomodulator and biologics unexposed (CON IBD). Data were prospectively collected in collaboration with specialised IBD pregnancy clinics for those in the control groups; data for the VDZE group were retrospectively collected. Differences in the groups existed; fewer VDZE women had Crohn's disease (CD) (55% compared to 83% TNFE) and greater percentages had clinically active disease based on the physician global assessment. In addition, VDZ discontinuation rates were high; 49% discontinued treatment during pregnancy and only 40 women continued VDZ throughout pregnancy. The rate of live born infants was lower in the VDZE compared to CON IBD group.
